Article Text

Download PDFPDF
Effects of selective serotonin reuptake inhibitors and other antidepressant drugs on the risk of hip fracture: a case–control study in an elderly Mediterranean population
  1. Maria Queralt Gorgas1,
  2. Ferran Torres2,3,
  3. Roser Vives4,
  4. Irene Lopez-Rico1,5,
  5. Dolors Capella6,
  6. Caridad Pontes7
  1. 1Pharmacy, Hospital Parc Taulí, Sabadell, Spain
  2. 2Biostatistics Unit. Facultat de Medicina, Universitat Autonoma de Barcelona, Bellaterra (Cerdanyola del Vallés), Spain
  3. 3Medical Statistics Core Facility. IDIBAPS, Hospital Clinic de Barcelona, Barcelona, Spain
  4. 4Departament de Farmacologia, de Terapèutica i de Toxicologia, Universitat Autonoma de Barcelona, Barcelona, Spain
  5. 5Pharmacology, Parc Taulí Hospital Universitari. Institut d'Invesigació i Innovació Parc Taulí I3PT. Universitat Autònoma de Barcelona, Sabadell, Spain
  6. 6Medical Sciences - TransLab Research Group, Universitat de Girona, Girona, Spain
  7. 7Departament de Farmacologia, de Terapèutica i de Toxicologia, Universitat Autonoma de Barcelona, Barcelona, Spain
  1. Correspondence to Dr Caridad Pontes, Departament de Farmacologia, de Terapèutica i de Toxicologia, Universitat Autonoma de Barcelona, Barcelona 08193, Spain; caridad.pontes{at}uab.cat

Abstract

Objectives To describe the association between exposure to different antidepressant drugs and hip fracture in an elderly Mediterranean population.

Methods Cases were all patients aged 50–95 years admitted to the emergency room of our hospital with hip fracture not related to a high intensity trauma during 2010. For each case, four controls were identified from primary care electronic medical records matched by age (±3 years), gender, date of consultation at the primary care centre (±1 month) and primary care centre. Pharmacological treatments received within the previous 5 years were retrieved from the prescription records. Crude and adjusted risks associated with exposures were calculated by conditional logistic regression. ORs were adjusted by matching variables and by significant risk factors identified in the bivariate analysis (prescription of ≥4 drugs, osteoporosis, diabetes mellitus and previous fracture).

Results 136 cases and 544 controls were analysed. Adjusted OR (95% CI) for hip fracture associated with exposure to any antidepressants was 2.42 (1.24 to 4.73); for selective serotonin reuptake inhibitors (SSRIs) it was 3.52 (1.67 to 7.41), for non-selective monoamine reuptake inhibitors 1.07 (0.18 to 6.46) and for other antidepressants 0.82 (0.27 to 2.48). Sertraline (OR 3.88 (1.15 to 13.09)) was the only active principle with significant adjusted risk. When only exposures >6 months were considered, significant risks persisted for SSRIs (OR 2.64 (1.10 to 6.37)).

Conclusions The results of this study are coincident with other studies in which SSRIs, but not other types of antidepressants, are associated with an increased risk of hip fracture in our setting.

  • selective serotonin reuptake inhibitors
  • fracture
  • antidepressant
  • case control study
  • osteoporosis
View Full Text

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.